Research Article
Inflammatory and Antioxidant Pattern Unbalance in “Clopidogrel-Resistant” Patients during Acute Coronary Syndrome
Table 1
Clinical characteristics between clopidogrel-responder and -nonresponder patients.
| | | Responders ( = 21) | Nonresponders ( = 8) | |
| | Age, years | 73 (60–80) | 78 (71–83) | 0.341 | | Male, (%) | 15 (71) | 4 (50) | 0.242 | | BMI, kg/m2 | 25 (23–27) | 26 (24–31) | 0.241 | | STEMI, (%) | 11 (52) | 5 (63) | 0.697 | | NSTEMI, (%) | 10 (48) | 3 (37) | 0.697 | | Lesion coronary artery, | 2 (1–3) | 1 (1-2) | 0.189 | | Three-vessel coronary artery disease, (%) | 7 (33) | 1 (13) | 0.381 | | Killip class, (%) | | | 0.804 | | 0 | 2 (10) | 1 (13) | | | 1 | 17 (85) | 7 (88) | | | 2 | 1 (5) | 0 (0) | | | Stent implantation, (%) | | | | | DES | 11 (52) | 1 (13) | 0.093 | | BMS | 9 (43) | 8 (100) | 0.009 | | Risk factors, (%) | | | | | Smoking | 8 (38) | 1 (13) | 0.371 | | Hypertension | 13 (62) | 5 (63) | 1.000 | | Hyperlipidemia | 4 (19) | 3 (38) | 0.357 | | Diabetes mellitus | 3 (14) | 5 (63) | 0.019 | | Family history of CAD | 1 (5) | 1 (13) | 0.483 | | Medical history, (%) | | | | | PCI | 1 (5) | 1 (13) | 0.483 | | CABG | 0 (0) | 1 (13) | 0.276 | | LEAD | 2 (10) | 0 (0) | 1.000 | | Ictus | 0 (0) | 0 (0) | — | | Renal failure | 1 (5) | 0 (0) | 1.000 | | Atrial fibrillation | 2 (10) | 1 (13) | 1.000 | | COPD | 2 (10) | 1 (13) | 1.000 | | Medical therapy, (%) | | | | | Ca-antagonist | 3 (14) | 1 (13) | 1.000 | | Ca-channel blockers | 0 (0) | 0 (0) | — | | ACEi | 13 (62) | 4 (50) | 0.683 | | ARB | 2 (10) | 1 (13) | 1.000 | | -blockers | 10 (48) | 5 (63) | 0.682 | | Statins | 21 (100) | 8 (100) | — | | GPIIb/IIIa inhibitors | 7 (33) | 3 (38) | 1.000 |
|
|
Data are expressed as median and interquartile range (25th–75th) or number (percentage).
ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; BMI: body mass index; Ca: calcium; BMS: bare metal coronary stent; CABG: coronary artery by-pass grafting; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; DES: drug-eluting stent; LEAD: lower extremity arterial disease; GP: glycoprotein; PCI: percutaneous coronary intervention; NSTEMI; non-ST-segment elevation myocardial infarction.
|
